Form 8-K

CVS HEALTH CORPORATION

Date: August 14, 2019

/s/ Eva C. Boratto

Eva C. Boratto

Executive Vice President and Chief Financial Officer

0001193125-19-221234.txt : 20190814 0001193125-19-221234.hdr.sgml : 20190814 20190814162703 ACCESSION NUMBER: 0001193125-19-221234 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20190814 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 191026826 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d774110d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2019

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	001-01011	05-0494040
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One CVS Drive, Woonsocket, Rhode Island		02895
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.01 per share

CVS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 8 - Other Events

Item 8.01.

Other Events

On August 14, 2019, CVS Health Corporation, a Delaware corporation (the “Company”), issued a press release announcing the pricing of its cash tender offers for (1) any and all of its 3.125% Senior Notes due 2020 and (2) any and all of its 4.125% Senior Notes due 2021, the 4.125% Senior Notes due 2021 issued by its wholly-owned subsidiary, Aetna Inc. (“Aetna”) and the 5.450% Senior Notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna, in connection with the Company’s previously announced cash tender offers commenced on August 8, 2019.

A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated by reference herein.

Section 9 - Financial Statements and Exhibits

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

The exhibit to this Current Report on Form 8-K is as follows:

INDEX TO EXHIBITS

99.1

Press Release of CVS Health Corporation dated August 14, 2019

104

Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d774110dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO


Investor	Valerie Haertel	Media	T.J. Crawford
Contact:	Senior Vice President	Contact:	Vice President
	Investor Relations		External Affairs
	(401) 770-4050		(212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Pricing of Any and All Tender Offers

WOONSOCKET, RI, August 14, 2019 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the applicable Reference Yields and Total Consideration (each as summarized in the tables below) to be paid in connection with the previously announced cash tender offers (the “Any and All Tender Offers,” and each an “Any and All Tender Offer”) for (1) any and all of its 3.125% Senior Notes due 2020 (the “2020 Any and All Notes”) and (2) any and all of its 4.125% Senior Notes due 2021, the 4.125% Senior Notes due 2021 issued by its wholly-owned subsidiary, Aetna Inc. (“Aetna”) and the 5.450% Senior Notes due 2021 issued by Coventry Health Care, Inc., a wholly-owned subsidiary of Aetna (collectively, the “2021 Any and All Notes” and together with the 2020 Any and All Notes, the “Any and All Notes”).

The applicable Reference Yield and Total Consideration for the Any and All Notes are summarized in the tables below:

2020 Any and All Notes:

Title of Notes

CUSIP
Number

Original
Issuer

Principal Amount
Outstanding

UST Reference
Security

Bloomberg
Reference Page

Fixed Spread
(bps)

Reference
Yield

Total
Consideration⁽¹⁾

3.125% Senior Notes due 2020

126650DA5

CVS Health Corporation

$2,000,000,000

1.625% UST due 03/15/2020

PX3

1.928%

$1,005.86

2021 Any and All Notes:

Title of Notes

CUSIP
Number

Original

Issuer

Principal Amount
Outstanding

UST Reference
Security

Bloomberg
Reference Page

Fixed Spread
(bps)

Reference
Yield

Total
Consideration⁽¹⁾

4.125% Senior Notes due 2021

126650BW9

CVS Health Corporation

$550,000,000

2.250% UST due 02/15/2021

PX4

1.662%

$1,033.32

4.125% Senior Notes due 2021

008117AN3

Aetna Inc.

$500,000,000

2.000% UST due 02/28/2021

PX4

1.657%

$1,034.37

5.450% Senior Notes due 2021

222862AJ3

Coventry Health Care, Inc.

$600,000,000

2.375% UST due 03/15/2021

PX4

37.5

1.650%

$1,053.11

(1)	Per $1,000 principal amount of Any and All Notes validly tendered at or prior to the Any and All Expiration Date and accepted for purchase.

The Any and All Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 8, 2019 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a more detailed description of the Any and All Tender Offers. Copies of the Offer to Purchase and the form of notice of guaranteed delivery with respect to the Any and All Notes (“Notice of Guaranteed Delivery”) are available at www.dfking.com/cvs. The Any and All Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Any and All Notes.

The Total Consideration for each $1,000 principal amount of the Any and All Notes was determined in the manner described in the Offer to Purchase by reference to the applicable fixed spread set forth in the tables above plus the yield to maturity of the applicable UST Reference Security set forth in the tables above on the bid-side price of such UST Reference Security as of 11:00 a.m., New York City time, on August 14, 2019.

Any and All Notes validly tendered and not validly withdrawn or those for which a properly completed and duly executed Notice of Guaranteed Delivery is delivered pursuant to the guaranteed delivery procedures described in the Offer to Purchase (the “Guaranteed Delivery Procedures”) at or prior to 5:00 p.m., New York City time, on August 14, 2019 (the “Any and All Expiration Date”) (unless extended by us as described in the Offer to Purchase) will be eligible to receive the applicable Total Consideration for the Any and All Notes.

The settlement date for the Any and All Notes validly tendered and not validly withdrawn at or prior to the Any and All Expiration Date and accepted for purchase is expected to be promptly after the expiration of the Any and All Tender Offers, which is expected to be August 15, 2019, the first business day after the Any and All Expiration Date (the “Any and All Settlement Date”). The settlement date for the Any and All Notes validly tendered pursuant to the Guaranteed Delivery Procedures at or prior to the Any and All Expiration Date and accepted for purchase is expected to be August 19, 2019, the second business day after the Any and All Settlement Date (the “Any and All Guaranteed Delivery Settlement Date”).

In addition to the Total Consideration for the Any and All Notes, Holders of the Any and All Notes accepted for purchase will receive accrued and unpaid interest (“Accrued Interest”) on those Any and All Notes from the last interest payment date with respect to those Any and All Notes to, but not including, the Any and All Settlement Date. For the avoidance of doubt, the Accrued Interest payable with respect to Any and All Notes validly tendered pursuant to the Guaranteed Delivery Procedures and accepted for purchase shall cease to accrue on the Any and All Settlement Date.

Holders who tender their Any and All Notes at or prior to 5:00 p.m., New York City time, on August 14, 2019 (such date and time, as it may be extended, the “Any and All Withdrawal Deadline”) may withdraw such tendered Any and All Notes at any time at or prior to the Any and All Withdrawal Deadline. Following the Any and All Withdrawal Deadline, Holders who have tendered their Any and All Notes (whether before, on or after the Any and All Withdrawal Deadline) may not withdraw such Any and All Notes unless CVS Health is required to extend withdrawal rights under applicable law.

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Any and All Tender Offers at any time prior to the Any and All Expiration Date. The Any and All Tender Offers are not conditioned on any minimum principal amount of Any and All Notes being tendered but the Any and All Tender Offers are subject to a financing condition and certain other general conditions as described in the Offer to Purchase.

CVS Health has retained Barclays Capital Inc. and Goldman Sachs & Co. LLC to act as Dealer Managers for the Tender Offers (as defined in the Offer to Purchase). D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offers. The Offer to Purchase and, in connection with the Any and All Notes, the Notice of Guaranteed Delivery may be accessed at the following link: http://www.dfking.com/cvs. Requests for assistance relating to the procedures for tendering Notes (as defined in the Offer to Purchase) may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (866) 406-2283 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offers may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect) or Goldman Sachs & Co. LLC at (800) 828-3182 (toll free) or (212) 902-2995 (collect). Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offers. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offers, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is the nation’s premier health innovation company helping people on their path to better health. Whether in one of its pharmacies or through its health services and plans, CVS Health is pioneering a bold new approach to total health by making quality care more affordable, accessible, simple and seamless. CVS Health is community-based and locally focused, engaging consumers with the care they need when and where they need it. The Company has approximately 9,900 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 102 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year and expanding specialty pharmacy services. CVS Health also serves an estimated 38 million people through traditional, voluntary and consumer-directed health insurance products and related services, including rapidly expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the section entitled “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K and in our most recently filed Quarterly Report on Form 10-Q.

You are cautioned not to place undue reliance on CVS Health’s forward looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

EX-101.SCH 3 cvs-20190814.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cvs-20190814_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cvs-20190814_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g774110g0814093737484.jpg GRAPHIC begin 644 g774110g0814093737484.jpg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end XML 7 d774110d8k_htm.xml IDEA: XBRL DOCUMENT 0000064803 2019-08-14 2019-08-14 CVS HEALTH Corp false 0000064803 8-K 2019-08-14 DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 (401) 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Aug. 14, 2019
Cover [Abstract]
Entity Registrant Name	CVS HEALTH Corp
Amendment Flag	false
Entity Central Index Key	0000064803
Document Type	8-K
Document Period End Date	Aug. 14, 2019
Entity Incorporation State Country Code	DE
Entity File Number	001-01011
Entity Tax Identification Number	05-0494040
Entity Address, Address Line One	One CVS Drive
Entity Address, City or Town	Woonsocket
Entity Address, State or Province	RI
Entity Address, Postal Zip Code	02895
City Area Code	(401)
Local Phone Number	765-1500
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	CVS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d774110d8k.htm cvs-20190814.xsd cvs-20190814_lab.xml cvs-20190814_pre.xml d774110dex991.htm g774110g0814093737484.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d774110d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d774110d8k.htm" ] }, "labelLink": { "local": [ "cvs-20190814_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cvs-20190814_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cvs-20190814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20190814", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d774110d8k.htm", "contextRef": "d_2019-08-14_to_2019-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d774110d8k.htm", "contextRef": "d_2019-08-14_to_2019-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-19-221234-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-221234-xbrl.zip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